Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRI102 in children with ADHD
NCT02083783Phase 3Completed
- Sponsor
- Tris Pharma
- Start
- Mar 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Tris Pharma. Started Mar 2014; status: completed.
02
Drugs
amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02083783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083783.